Clearside Biomedical IncNASDAQ:CLSD
- LAST PRICE1.3000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.3000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLSD |
|---|---|---|
| 09:32 ET | 437 | 1.28 |
| 09:34 ET | 200 | 1.2773 |
| 09:43 ET | 350 | 1.26 |
| 09:52 ET | 110 | 1.28 |
| 10:06 ET | 400 | 1.26 |
| 10:21 ET | 100 | 1.275 |
| 10:28 ET | 133 | 1.28 |
| 10:37 ET | 150 | 1.285 |
| 10:50 ET | 100 | 1.285 |
| 11:11 ET | 100 | 1.28 |
| 11:18 ET | 100 | 1.28 |
| 11:20 ET | 343 | 1.2805 |
| 11:22 ET | 250 | 1.285 |
| 11:26 ET | 100 | 1.28 |
| 11:31 ET | 100 | 1.28 |
| 11:42 ET | 100 | 1.28 |
| 11:49 ET | 100 | 1.28 |
| 11:51 ET | 2289 | 1.29 |
| 11:56 ET | 100 | 1.285 |
| 11:58 ET | 100 | 1.285 |
| 12:07 ET | 2000 | 1.2802 |
| 12:09 ET | 300 | 1.2899 |
| 12:16 ET | 200 | 1.28 |
| 12:20 ET | 100 | 1.28 |
| 12:21 ET | 4855 | 1.295 |
| 12:23 ET | 500 | 1.29 |
| 12:25 ET | 100 | 1.29 |
| 12:32 ET | 250 | 1.285 |
| 12:43 ET | 100 | 1.28 |
| 12:52 ET | 100 | 1.28 |
| 12:57 ET | 100 | 1.28 |
| 01:06 ET | 300 | 1.28 |
| 01:12 ET | 2400 | 1.275 |
| 01:14 ET | 100 | 1.27 |
| 01:24 ET | 100 | 1.28 |
| 01:26 ET | 200 | 1.28 |
| 01:30 ET | 100 | 1.29 |
| 01:37 ET | 350 | 1.271 |
| 01:50 ET | 100 | 1.27 |
| 01:53 ET | 5600 | 1.29 |
| 01:55 ET | 100 | 1.295 |
| 01:57 ET | 510 | 1.3 |
| 02:00 ET | 100 | 1.3 |
| 02:04 ET | 100 | 1.295 |
| 02:11 ET | 100 | 1.29 |
| 02:13 ET | 100 | 1.295 |
| 02:18 ET | 9795 | 1.285 |
| 02:31 ET | 100 | 1.27 |
| 02:40 ET | 100 | 1.27 |
| 02:47 ET | 100 | 1.27 |
| 02:58 ET | 100 | 1.27 |
| 03:05 ET | 100 | 1.26 |
| 03:12 ET | 100 | 1.26 |
| 03:18 ET | 100 | 1.26 |
| 03:23 ET | 200 | 1.2898 |
| 03:30 ET | 100 | 1.26 |
| 03:32 ET | 100 | 1.275 |
| 03:36 ET | 100 | 1.26 |
| 03:41 ET | 100 | 1.26 |
| 03:45 ET | 200 | 1.26 |
| 03:50 ET | 100 | 1.26 |
| 03:52 ET | 8385 | 1.29 |
| 03:54 ET | 2600 | 1.29 |
| 03:56 ET | 1879 | 1.2801 |
| 03:57 ET | 441 | 1.28 |
| 03:59 ET | 2600 | 1.3 |
Jun 27, 2024
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery, from 7:05AM ET on Thursday Jun 27, 2024 by Dow Jones
7:05AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 25, 2024
DJ Clearside Biomedical Initiated at Outperform by Oppenheimer, from 5:54AM ET on Tuesday Jun 25, 2024 by Dow Jones
5:54AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 12, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clearside Biomedical Inc | 97.2M | -2.4x | --- |
Affimed NV | 83.0M | -0.8x | --- |
Coya Therapeutics Inc | 92.2M | -6.8x | --- |
Ikena Oncology Inc | 79.6M | -1.0x | --- |
Vaxart Inc | 118.0M | -1.2x | --- |
Armata Pharmaceuticals Inc | 99.4M | -1.2x | --- |
Company Information
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Contact Information
- Headquarters
- 900 North Point Parkway, Suite 200ALPHARETTA, GA, United States 30005
- Phone
- 678-270-3631
- Fax
- 678-270-4033
Executives
- Independent Chairman of the Board
- William Humphries
- President, Chief Executive Officer, Director
- George Lasezkay
- Chief Financial Officer
- Charles Deignan
- Chief Medical Officer
- Victor Chong
- Director
- Anthony Gibney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $97.2M |
|---|---|
Revenue (TTM) | $8.5M |
Shares Outstanding | 74.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.43 |
EPS | $-0.54 |
Book Value | $-0.25 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 11.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -282.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
